Show menu

Trustworthy development and commercial manufacturing of CELL&GENE therapies.

  • On december 1st 2023, Seqens completed the acquisition of CELLforCURE
  • Originally a versatile CELL&GENE CDMO, CELLforCURE gained thorough experience in commercial CAR-T cells manufacturing
  • CELLforCURE teams aim at partnering with innovators to develop and manufacture CELL&GENE therapies for today and tomorrow


Site Facility
With 2 200m2 GMP production areas, 6 equipped production suites and 180 seasoned highly skilled experts, CELLforCURE offers versatile and flexible capacities CELLforCURE is located in France, 20km away from the Paris Orly Airport.
Technologies & Equipment
CELLforCURE is an EMA approved production site and is compliant with FDA standards. The site brings analytical, development and regulatory services to serve client needs across the overall product life cycle.

Key Figures

Autologous batches / day validated capacity
10 years
of Experience in CELL&GENE therapy
GMP classified production area

What makes us sustainable

Know more

Corporate Social Responsibility can be defined as the integration by companies of social and environmental concerns in their activities and their relations with stakeholders.

As a global player in pharmaceutical solutions and specialty ingredients, SEQENS is committed to making corporate social responsibility a priority.


Take science that accelerates progress to the next level